Barinthus Biotherapeutics completed enrollment for two clinical trials: HBV003, a Phase 2b clinical trial of VTP-300 in adults with chronic hepatitis B; and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen after definitive local therapy for prostate cancer. Interim data update for HBV003 is anticipated in Q4. Data update for PCA001 is anticipated in H1 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000
- Barinthus Biotherapeutics Elevates Griffiths to COO
- Barinthus price target lowered to $9.50 from $11 at Alliance Global Partners
- Barinthus Biotherapeutics reports Q2 EPS (43c), consensus (41c)